July 30- Novo Nordisk (NYSE:NVO) continued to slide 7% on Wednesday after the Danish drugmaker cut its full?year outlook. Slower growth in its obesity franchise, led by semaglutide, weighed down the company’s performance. Novo Nordisk (NVO) Sell-Off Wipes Billions in Market Value The company now sees sales rising 8%14% and …
Read More »Novo Nordisk (NVO) Sell-Off Wipes Billions in Market Value
